Federico Maria Gioacchini1, Shaniko Kaleci2, Giuseppe Chiarella3, Pasquale Viola3, Davide Pisani3, Alfonso Scarpa4, Michele Tulli5, Annalisa Pace6, Giannicola Iannella6, Massimo Re5. 1. Department of Clinical and Molecular Sciences, ENT Unit, Polytechnic University of Marche, Ancona, Italy. giox83@hotmail.com. 2. Department of Diagnostic Medicine, Clinical and Public Health, University Hospital of Modena, Modena, Italy. 3. Unit of Audiology, Department of Experimental and Clinical Medicine, Regional Centre of Cochlear Implants and ENT Diseases, Magna Graecia University, Catanzaro, Italy. 4. Department of Medicine and Surgery, University of Salerno, Salerno, Italy. 5. Department of Clinical and Molecular Sciences, ENT Unit, Polytechnic University of Marche, Ancona, Italy. 6. Department of Sense Organs, Sapienza University Rome, Rome, Italy.
Abstract
PURPOSE: Most ELST data in the literature are case studies or limited to small cohorts (< 16 patients). We evaluated the main clinical signs observed at endolymphatic sac tumor (ELST) diagnosis in patients with or without Von Hippel-Lindau disease. METHODS: We conducted a comprehensive literature search in PubMed, Scopus, and Web of Science. We included studies with at least 1 patient, of any age, affected by sporadic or VHL-related ELSTs reporting levels of hearing loss and facial nerve function and a comprehensive description of presenting symptoms at ELST diagnosis. We combined data for proportional meta-analysis. p values of 0.05 were considered statistically significant. Methodological quality was evaluated. Analyses were performed with MedCalc 14.8.1 software. RESULTS: A total of 26 studies, including 113 patients and 118 cases of ELSTs were included. Pooled proportion rates (95% CI) of overall hearing loss was 88.7%, (82.4-93.4), severe hearing loss was 21.6% (12.8-32.1) profound hearing loss was 39.8% (28.7-51.5), vertigo/imbalance was 42.0% (33.8-50.5), tinnitus was 61.8% (53.4-69.8) and facial nerve palsy was 30.6% (23.2-38.9). Generally, symptoms were homogeneous or moderately heterogeneous among included studies. CONCLUSION: This is the first systematic review of clinical presentations at ELST diagnosis. The most serious clinical events include profound hearing loss and facial impairment. Fluctuating hearing loss, tinnitus and vertigo are frequently reported and may confound correct and prompt ELST diagnosis.
PURPOSE: Most ELST data in the literature are case studies or limited to small cohorts (< 16 patients). We evaluated the main clinical signs observed at endolymphatic sac tumor (ELST) diagnosis in patients with or without Von Hippel-Lindau disease. METHODS: We conducted a comprehensive literature search in PubMed, Scopus, and Web of Science. We included studies with at least 1 patient, of any age, affected by sporadic or VHL-related ELSTs reporting levels of hearing loss and facial nerve function and a comprehensive description of presenting symptoms at ELST diagnosis. We combined data for proportional meta-analysis. p values of 0.05 were considered statistically significant. Methodological quality was evaluated. Analyses were performed with MedCalc 14.8.1 software. RESULTS: A total of 26 studies, including 113 patients and 118 cases of ELSTs were included. Pooled proportion rates (95% CI) of overall hearing loss was 88.7%, (82.4-93.4), severe hearing loss was 21.6% (12.8-32.1) profound hearing loss was 39.8% (28.7-51.5), vertigo/imbalance was 42.0% (33.8-50.5), tinnitus was 61.8% (53.4-69.8) and facial nerve palsy was 30.6% (23.2-38.9). Generally, symptoms were homogeneous or moderately heterogeneous among included studies. CONCLUSION: This is the first systematic review of clinical presentations at ELST diagnosis. The most serious clinical events include profound hearing loss and facial impairment. Fluctuating hearing loss, tinnitus and vertigo are frequently reported and may confound correct and prompt ELST diagnosis.
Authors: Alessandro Liberati; Douglas G Altman; Jennifer Tetzlaff; Cynthia Mulrow; Peter C Gøtzsche; John P A Ioannidis; Mike Clarke; P J Devereaux; Jos Kleijnen; David Moher Journal: Ann Intern Med Date: 2009-07-20 Impact factor: 25.391
Authors: Cliff A Megerian; David S Haynes; Dennis S Poe; Daniel I Choo; Thomas J Keriakas; Michael E Glasscock Journal: Otol Neurotol Date: 2002-05 Impact factor: 2.311
Authors: Arturo Mario Poletti; Siba Prasad Dubey; Giovanni Colombo; Giovanni Cugini; Antonio Mazzoni Journal: Rep Pract Oncol Radiother Date: 2015-07-30
Authors: John A Butman; H Jeffrey Kim; Martin Baggenstos; Joshua M Ammerman; James Dambrosia; Athos Patsalides; Nicholas J Patronas; Edward H Oldfield; Russell R Lonser Journal: JAMA Date: 2007-07-04 Impact factor: 56.272